{"id":"oral-levetiracetam","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Behavioral/mood changes"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1286","moleculeType":"Small molecule","molecularWeight":"170.21"},"_dailymed":{"setId":"0bc8468f-832c-4e71-95a2-db464d4d54bc","title":"LEVETIRACETAM (LEVETIRACETAM ORAL) SOLUTION [CAMBER PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby decreasing seizure susceptibility. The exact mechanism is not fully elucidated, but SV2A binding is considered the primary molecular action responsible for its antiepileptic effects.","oneSentence":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:42.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial-onset seizures)"},{"name":"Epilepsy (adjunctive therapy for myoclonic seizures)"},{"name":"Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures)"}]},"trialDetails":[{"nctId":"NCT07490769","phase":"PHASE3","title":"Levetiracetam Three Times Daily in Epilepsy","status":"RECRUITING","sponsor":"Waad Alkathiri","startDate":"2025-10-01","conditions":"Epilepsy","enrollment":120},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07271966","phase":"NA","title":"B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-30","conditions":"Brain Tumor Related Epilepsy (BTRE)","enrollment":50},{"nctId":"NCT07422233","phase":"PHASE4","title":"Evaluation of Levetiracetam's Effectiveness and Tolerability for Treating Epilepsy in Older Adults","status":"COMPLETED","sponsor":"Nasim Tabrizi","startDate":"2023-09-13","conditions":"Epilepsy, Elderly","enrollment":137},{"nctId":"NCT07393022","phase":"PHASE1","title":"Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2025-12-17","conditions":"Pharmacokinetic Analysis, Bioequivalence, Health Adult Subjects","enrollment":20},{"nctId":"NCT06866691","phase":"PHASE4","title":"Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-04-18","conditions":"Traumatic Brain Injury","enrollment":600},{"nctId":"NCT07336992","phase":"PHASE3","title":"Efficacy of Prophylactic Levetiracetam for Improving Functional Outcome in the Acute Phase of Intracerebral Haemorrhage: a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-01-02","conditions":"Spontaneous Intracerebral Hemorrhage","enrollment":580},{"nctId":"NCT07284498","phase":"PHASE4","title":"Treatment of Seizures in Neonate With HIE","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-01-01","conditions":"Neonatal Seizures, HIE - Hypoxic - Ischemic Encephalopathy","enrollment":66},{"nctId":"NCT07239115","phase":"PHASE3","title":"Levetiracetam for Seizure Prevention After Brain Tumor Surgery","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-01","conditions":"Postoperative Seizures After Brain Tumor Surgery","enrollment":558},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT07220902","phase":"PHASE3","title":"Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure","status":"NOT_YET_RECRUITING","sponsor":"Nebraska Methodist Health System","startDate":"2026-01-01","conditions":"Severe Preeclampsia, Eclampsia Preeclampsia","enrollment":1240},{"nctId":"NCT02631759","phase":"PHASE3","title":"Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-10","conditions":"Acute intraCerebral Haemorrhage","enrollment":50},{"nctId":"NCT07163585","phase":"NA","title":"Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2024-08-01","conditions":"Epilepsy","enrollment":102},{"nctId":"NCT07072624","phase":"PHASE4","title":"Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Jodhpur","startDate":"2025-07-23","conditions":"Seizures, Traumatic Brain Injuries, Traumatic Brain Injury (TBI) Patients","enrollment":1260},{"nctId":"NCT05756621","phase":"","title":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2022-01-15","conditions":"Status Epilepticus, Cardiac Arrest","enrollment":80},{"nctId":"NCT04836559","phase":"PHASE2","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-18","conditions":"Focal Onset Seizures","enrollment":110},{"nctId":"NCT05986721","phase":"PHASE2","title":"Clinical Trial of AGB101 for Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"AgeneBio","startDate":"2024-12-03","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease","enrollment":""},{"nctId":"NCT06773364","phase":"PHASE3","title":"Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-04-30","conditions":"Suspected Stroke","enrollment":2423},{"nctId":"NCT01228747","phase":"PHASE3","title":"A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2010-10","conditions":"Epilepsy, Generalized Tonic-Clonic Seizures","enrollment":361},{"nctId":"NCT03875638","phase":"PHASE2","title":"Treating Hyperexcitability in AD With Levetiracetam","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-08-22","conditions":"Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type","enrollment":85},{"nctId":"NCT01801072","phase":"PHASE4","title":"Seizure Prophylaxis in Aneurysm Repair","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2013-02","conditions":"Intracranial Aneurysms, Seizure","enrollment":82},{"nctId":"NCT05897658","phase":"PHASE3","title":"Levetiracetam Prophylaxis in Brain Tumor Resection Pilot","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-03","conditions":"Seizures, Brain Tumor","enrollment":70},{"nctId":"NCT04497142","phase":"PHASE1, PHASE2","title":"Effect of Perampanel on Peritumoral Hyperexcitability in HGG","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-05","conditions":"Glioma, Malignant, Surgery, Seizures","enrollment":12},{"nctId":"NCT03340064","phase":"PHASE3","title":"A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2017-11-30","conditions":"Partial Seizures","enrollment":38},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT03489044","phase":"PHASE2","title":"An Investigation of Levetiracetam in Alzheimer's Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-10-28","conditions":"Alzheimer Disease, Epilepsy","enrollment":8},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT00150709","phase":"PHASE3","title":"A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1998-01-26","conditions":"Epilepsy, Partial","enrollment":223},{"nctId":"NCT02550028","phase":"PHASE1, PHASE2","title":"Levetiracetam Treatment of Neonatal Seizures","status":"TERMINATED","sponsor":"Children's Hospital of Fudan University","startDate":"2015-09-01","conditions":"Neonatal Seizures","enrollment":60},{"nctId":"NCT00152503","phase":"PHASE2","title":"Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2005-08-31","conditions":"Epilepsy, Partial","enrollment":59},{"nctId":"NCT05860153","phase":"NA","title":"Intermittent Levetricetam in Treatment of Febrile Convulsions","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06-01","conditions":"Febrile Convulsion","enrollment":100},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03129360","phase":"PHASE2","title":"Levetiracetam in Early Psychosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-18","conditions":"Psychosis, Schizophrenia, Schizo Affective Disorder","enrollment":48},{"nctId":"NCT02334722","phase":"PHASE4","title":"1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2015-08-05","conditions":"Brain Neoplasms, Brain Cancer, Brain Tumors","enrollment":81},{"nctId":"NCT04277936","phase":"PHASE2","title":"Pharmacologic Modulation of Hippocampal Activity in Psychosis","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-05-11","conditions":"Schizophrenia; Psychosis","enrollment":1},{"nctId":"NCT04858841","phase":"NA","title":"Post-stroke Epilepsy: Primary Prophylaxis Study","status":"UNKNOWN","sponsor":"National Cheng Kung University","startDate":"2020-08-01","conditions":"Middle Cerebral Artery Stroke","enrollment":180},{"nctId":"NCT00227461","phase":"PHASE1","title":"Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2005-09","conditions":"Aphasia, Stroke","enrollment":50},{"nctId":"NCT00537238","phase":"PHASE3","title":"Pregabalin Versus Levetiracetam In Partial Seizures","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10","conditions":"Partial Seizures","enrollment":509},{"nctId":"NCT00367432","phase":"PHASE3","title":"A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2006-07","conditions":"Epilepsies, Partial","enrollment":398},{"nctId":"NCT04573803","phase":"PHASE3","title":"Pharmacological Management of Seizures Post Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-03-01","conditions":"Traumatic Brain Injury, Post Traumatic Seizures","enrollment":1649},{"nctId":"NCT00175890","phase":"PHASE3","title":"A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-10","conditions":"Epilepsy, Partial","enrollment":116},{"nctId":"NCT00160654","phase":"PHASE4","title":"Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-11-24","conditions":"Epilepsy, Partial","enrollment":251},{"nctId":"NCT03490487","phase":"PHASE4","title":"Electroclinical Effect of Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-06-20","conditions":"Benign Childhood Epilepsy With Centrotemporal Spikes","enrollment":100},{"nctId":"NCT00615615","phase":"PHASE3","title":"Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1999-09","conditions":"Epilepsy","enrollment":216},{"nctId":"NCT00150748","phase":"PHASE3","title":"Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2001-11","conditions":"Generalized Epilepsy","enrollment":217},{"nctId":"NCT00368069","phase":"PHASE3","title":"A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-08","conditions":"Epilepsy","enrollment":158},{"nctId":"NCT02707965","phase":"PHASE1","title":"Characterization of Epilepsy Patients BEEP 2b","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2017-06-08","conditions":"Epilepsy","enrollment":21},{"nctId":"NCT00160615","phase":"PHASE3","title":"Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2001-09-12","conditions":"Epilepsy, Partial","enrollment":154},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT00150813","phase":"PHASE3","title":"Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2005-08-10","conditions":"Epilepsy, Tonic-clonic","enrollment":66},{"nctId":"NCT01318408","phase":"PHASE4","title":"Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2006-11","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT00916149","phase":"NA","title":"Cognitive Effects of Treatment of Interictal Discharges","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT01935908","phase":"PHASE4","title":"Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2013-05","conditions":"Subarachnoid Hemorrhage, Seizures","enrollment":""},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT01398956","phase":"PHASE3","title":"An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-06","conditions":"Epilepsy, Generalized Tonic-clonic Seizures","enrollment":44},{"nctId":"NCT03107507","phase":"PHASE4","title":"Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2017-03-25","conditions":"Neonatal Seizures","enrollment":40},{"nctId":"NCT01392768","phase":"PHASE3","title":"Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-01","conditions":"Epilepsy, Partial Seizures","enrollment":126},{"nctId":"NCT01982812","phase":"PHASE2","title":"A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-01","conditions":"Seizure, Epilepsy, Cerebral Malaria","enrollment":44},{"nctId":"NCT01974700","phase":"PHASE4","title":"Seizure Prophylaxis in Aneurysm Repair","status":"TERMINATED","sponsor":"Indiana University","startDate":"2013-07","conditions":"Intracranial Aneurysms, Seizures","enrollment":17},{"nctId":"NCT01506882","phase":"PHASE3","title":"An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2011-12","conditions":"Epilepsy, Partial Onset Seizures","enrollment":71},{"nctId":"NCT00505934","phase":"PHASE2","title":"Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2008-05","conditions":"Epilepsy","enrollment":19},{"nctId":"NCT00376766","phase":"PHASE3","title":"Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2007-02","conditions":"Epilepsy, Drug Resistant","enrollment":112},{"nctId":"NCT00291655","phase":"PHASE3","title":"Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06","conditions":"Epilepsy","enrollment":130},{"nctId":"NCT01292837","phase":"PHASE3","title":"A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2011-02","conditions":"Epilepsy, Generalized Tonic-clonic Seizures","enrollment":13},{"nctId":"NCT00862563","phase":"PHASE2","title":"Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Alcohol Abuse","enrollment":85},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT00175903","phase":"PHASE3","title":"Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-02","conditions":"Epilepsy","enrollment":1701},{"nctId":"NCT01063764","phase":"PHASE3","title":"An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2010-01","conditions":"Epilepsy, Partial Seizures","enrollment":73},{"nctId":"NCT00105040","phase":"PHASE2","title":"A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-09","conditions":"Epilepsy, Partial","enrollment":87},{"nctId":"NCT00280696","phase":"PHASE3","title":"A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2005-11","conditions":"Epilepsies, Partial","enrollment":352},{"nctId":"NCT01210690","phase":"","title":"Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-01","conditions":"Epilepsy","enrollment":101},{"nctId":"NCT01491113","phase":"PHASE4","title":"Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-11","conditions":"Healthy Subjects, Renal Impairments","enrollment":30},{"nctId":"NCT00175955","phase":"PHASE2","title":"Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-05","conditions":"Dyskinesia, Medication-induced","enrollment":70},{"nctId":"NCT00160576","phase":"PHASE2","title":"Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-07","conditions":"Idiopathic Parkinson Disease","enrollment":30},{"nctId":"NCT00150787","phase":"PHASE3","title":"Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2003-07","conditions":"Epilepsy, Tonic-clonic","enrollment":250},{"nctId":"NCT00150735","phase":"PHASE3","title":"Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-06","conditions":"Generalized Epilepsy","enrollment":580},{"nctId":"NCT00160550","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-09","conditions":"Generalized Convulsive Epilepsy","enrollment":154},{"nctId":"NCT00544050","phase":"PHASE2","title":"Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-09","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT00150774","phase":"PHASE3","title":"Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-11","conditions":"Generalized Convulsive Epilepsy","enrollment":116},{"nctId":"NCT01407523","phase":"PHASE2","title":"An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2011-07","conditions":"Epilepsy, Partial Onset Seizures","enrollment":16},{"nctId":"NCT00438451","phase":"PHASE4","title":"Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2007-01","conditions":"Focal Epilepsy","enrollment":361},{"nctId":"NCT00152516","phase":"PHASE3","title":"Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-10","conditions":"Epilepsy, Partial","enrollment":255},{"nctId":"NCT01618877","phase":"PHASE1","title":"A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Human Volunteers","enrollment":24},{"nctId":"NCT01618903","phase":"PHASE1","title":"An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Human Volunteers","enrollment":24},{"nctId":"NCT00566046","phase":"PHASE3","title":"Prevention of Post-traumatic Seizures With Levetiracetam","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2007-11","conditions":"Epilepsy, Post-Traumatic","enrollment":23},{"nctId":"NCT00319605","phase":"","title":"Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-04","conditions":"Epilepsy","enrollment":600},{"nctId":"NCT00985348","phase":"PHASE1","title":"Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09","conditions":"Healthy","enrollment":26},{"nctId":"NCT01394224","phase":"PHASE1","title":"Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-06","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT00535392","phase":"PHASE2","title":"Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT00571155","phase":"PHASE4","title":"Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2007-12","conditions":"Primary Brain Tumor, Epilepsy","enrollment":30},{"nctId":"NCT00926302","phase":"NA","title":"A Bioequivalence Study of Levetiracetam Versus Keppra","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2008-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keppra","Iracet Injection","Neurocet Injection","levetiracetam"],"phase":"marketed","status":"active","brandName":"Oral levetiracetam","genericName":"Oral levetiracetam","companyName":"Children's Hospital of Fudan University","companyId":"children-s-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release. Used for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}